Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD versus VELSIPITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD versus VELSIPITY.
FINGOLIMOD vs VELSIPITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
Sphingosine 1-phosphate (S1P) receptor modulator; selectively binds to S1P receptor subtypes 1, 4, and 5, inhibiting lymphocyte egress from lymphoid tissues, thereby reducing circulating lymphocytes.
0.5 mg orally once daily
0.23 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Clinical Note
moderateFingolimod + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Isavuconazonium
Terminal elimination half-life is approximately 20 days. This long half-life allows for weekly oral dosing and requires a prolonged washout period before initiating other treatments.
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Primarily eliminated via biliary/fecal route (approximately 70% as unchanged drug) and renal excretion (approximately 30% as unchanged drug and metabolites, with less than 1% as unchanged drug in urine).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator
"The metabolism of Isavuconazonium can be decreased when combined with Fingolimod."